Molecular determinants of resistance to antiandrogen therapy
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy. This increase in androgen receptor mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional ligand-binding domain. Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand, and by altering the normal response to antagonists. These findings provide insight toward the design of new antiandrogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“which is known to promote AI-type growth in human prostate cancer models (3)”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [35]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“Because xenograft-specific expression signatures are likely to obscure the gene expression changes responsible for the transition from hormone-sensitive to hormone-refractory state”
BackgroundShiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729 · cited 1×
“Because steroid receptor–antagonist complexes adopt a variety of conformation”
BackgroundThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“The postulated mechanisms to explain resistance to hormone therapy can be separated into three general categorie”
BackgroundThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · cited 1×
“The kinases and substrates responsible for androgen receptor activation in this setting are unknown, but it is presumed to occur through downstream phosphorylation of androgen receptor–associated proteins or through the androgen receptor itself, analogous to the estrogen recepto”
BackgroundLNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146 · cited 1×
“Previous work has shown that the agonist-versus-antagonist response of nuclear receptors, such as the estrogen receptor, is altered by increased expression of coactivators (such as SRC-1) or by decreased expression of corepressors (such as NCoR”
BackgroundNongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113
Cited by
Items 501–600 of 1,002
Lin, B., Wang, J., Hong, X., Yan, X., Hwang, D., Cho, J.-H., Yi, D., Utleg, A. G., Fang, X., Schones, D. E., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006589 · Cited by 81
“Alterations in AR sequences and expression levels and perturbations in AR signaling networks have significant roles in the genesis and maintenance of prostate cancers (PCa) [1–6].”
Baek, S. H., Ohgi, K. A., Nelson, C. A., Welsbie, D., Chen, C., Sawyers, C. L., Rose, D. W., & Rosenfeld, M. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510842103 · Cited by 81
Self-citationHypoxia Increases Androgen Receptor Activity in Prostate Cancer Cells
Park, S.-Y., Kim, Y.-J., Gao, A. C., Mohler, J. L., Onate, S. A., Hidalgo, A. A., Ip, C., Park, E.-M., Yoon, S. Y., & Park, Y.-M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1341 · Cited by 81
“Although alterations of the AR gene have been correlated with response to androgen deprivation therapy, the majority of patients do not have AR mutations or amplification, and retain active AR signaling (29, 30).”
BackgroundWu, K., Katiyar, S., Witkiewicz, A., Li, A., McCue, P. A., Song, L., Tian, L., Jin, M. L., & Pestell, R. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3821 · Cited by 85
“Hyperactivation of the androgen receptor (AR) is a fundamental driver of prostate cancer progression (3), and AR”
Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer
Ashikari, D., Takayama, K., Tanaka, T., Suzuki, Y., Obinata, D., Fujimura, T., Urano, T., Takahashi, S., & Inoue, S. (2017) · Oncogene · doi:10.1038/onc.2017.225 · Cited by 83
Marques, R. B., Erkens‐Schulze, S., de Ridder, C. M., Hermans, K. G., Waltering, K. K., Visakorpi, T., Trapman, J., Romijn, J. C., van Weerden, W. M., & Jenster, G. W. (2005) · International Journal of Cancer · doi:10.1002/ijc.21201 · Cited by 90
“Although Chen et al.(10) previously suggested that increased AR levels conferred agonistic activity to AR antagonists, we did not observe AR stimulation by OH-flutamide in the PC346Flu1 line.”
BackgroundGene expression microarray technologies in the development of new therapeutic agents
Clarke, P. A., Poele, R. T., & Workman, P. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.07.024 · Cited by 86
“Comparison of hormone-sensitive and hormone-refractory human prostate cancer xenograft pairs by gene expression profiling identified the androgen receptor as the only gene differentially expressed in all the hormone-refractory tumours [85].”
BackgroundAndrogen–glucocorticoid interactions in the era of novel prostate cancer therapy
Narayanan, S., Srinivas, S., & Feldman, D. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.254 · Cited by 90
Schweizer, M. T., Wang, H., Luber, B. S., Nadal, R., Spitz, A. N., Rosen, D. M., Cao, H., Antonarakis, E. S., Eisenberger, M. A., Carducci, M. A., et al. (2016) · The Prostate · doi:10.1002/pros.23209 · Cited by 80
Lin, H.-P., Lin, C., Huo, C., Hsiao, P.-H., Su, L., Jiang, S. S., Chan, T.-M., Chang, C.-H., Chen, L., Kung, H.-J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3246 · Cited by 85
Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer
Nakabayashi, M., Werner, L., Courtney, K. D., Buckle, G. C., Oh, W. K., Bubley, G. J., Hayes, J. H., Weckstein, D. J., Elfiky, A. A., Sims, D. M., et al. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11456.x · Cited by 82
Switching and withdrawing hormonal agents for castration-resistant prostate cancer
Lorente, D., Mateo, J., Zafeiriou, Z., Smith, A. D., Sandhu, S. K., Ferraldeschi, R., & Bono, J. S. D. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2014.345 · Cited by 98
Loddick, S. A., Ross, S. J., Thomason, A. G., Robinson, D. M., Walker, G. E., Dunkley, T. P. J., Brave, S. R., Broadbent, N., Stratton, N. C., Trueman, D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1174 · Cited by 79
“These include; an increase in the expression of AR protein which can sensitize cells to low levels of androgen (8-11), AR mutations that can alter transactivation or sensitize AR to alternative ligands (3,5) and those that cause classical AR antagonists such as flutamide and bicalutamide to behave as agonists (12,13).”
BackgroundTitanium‐Mediated Amination of Grignard Reagents Using Primary and Secondary Amines
Barker, T. J., & Jarvo, E. R. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201103700 · Cited by 79
Transcriptional network of androgen receptor in prostate cancer progression
Takayama, K., & Inoue, S. (2013) · International Journal of Urology · doi:10.1111/iju.12146 · Cited by 90
Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival
Rokhlin, O. W., Taghiyev, A. F., Bayer, K. U., Bumcrot, D. A., Koteliansky, V., Glover, R. A., & Cohen, M. B. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.5.3975 · Cited by 87
“Apparently, CaMKII can mediate its anti-apoptotic activities through at least three different pathways: (1) via Akt activation; (2) via activation of AR, especially in ADI conditions; (3) by direct (or indirect) inhibition of a pro-apoptotic factor(s).”
BackgroundRajan, P., Gaughan, L., Dalgliesh, C., El‐Sherif, A., Robson, C. N., Leung, H. Y., & Elliott, D. J. (2008) · The Journal of Pathology · doi:10.1002/path.2324 · Cited by 81
“The transcription function of the androgen receptor (AR), a nuclear hormone receptor, drives the onset and progression of prostate cancer (PCa), and the AR-signalling cascade can remain active in hormonerefractory disease [17].”
BackgroundBanach-Petrosky, W. A., Jessen, W. J., Ouyang, X., Gao, H., Rao, J., Quinn, J., Aronow, B. J., & Abate-Shen, C. T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2887 · Cited by 84
PTP1B Is an Androgen Receptor–Regulated Phosphatase That Promotes the Progression of Prostate Cancer
Lessard, L., Labbé, D. P., Deblois, G., Bégin, L. R., Hardy, S., Mes-Masson, A.-M., Saad, F., Trotman, L. C., Giguère, V., & Tremblay, M. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2602 · Cited by 79
“on the AR for their growth and survival, a feature that underscores the "addiction" of prostate cancer cells to AR signaling (4, 5).”
BackgroundHuber, S. M. (2013) · Cell Calcium · doi:10.1016/j.ceca.2013.01.001 · Cited by 87
From pathogenesis to prevention of castration resistant prostate cancer
Bonkhoff, H., & Berges, R. R. (2009) · The Prostate · doi:10.1002/pros.21042 · Cited by 90
“Experimental data have convincingly demonstrated that upregulation of the AR at the mRNA and protein level is sufficient to convert castration sensitive to CR growth [3].”
BackgroundInfluentialAndrogen receptor–cofactor interactions as targets for new drug discovery
Chang, C., & McDonnell, D. P. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.002 · Cited by 84
Androgen receptor mediates the expression of UDP‐glucuronosyltransferase 2 B15 and B17 genes
Bao, B., Chuang, B., Wang, Q., Sartor, O., Balk, S. P., Brown, M., Kantoff, P. W., & Lee, G. M. (2008) · The Prostate · doi:10.1002/pros.20749 · Cited by 79
Gustavsson, H., Welén, K., & Damber, J. (2004) · The Prostate · doi:10.1002/pros.20145 · Cited by 84
“tion or modulation of the androgen receptor is one possible mechanism, and gene amplification of the androgen receptor has been found in 30% of androgen-resistant prostate tumors [3,4].”
BackgroundIdentification of βArrestin2 as a corepressor of androgen receptor signaling in prostate cancer
Lakshmikanthan, V., Zou, L., Kim, J. I., Michal, A. M., Nie, Z., Messias, N. C., Benovic, J., & Daaka, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900258106 · Cited by 78
“In some prostate cancers, increased AR expression or activity (via activating mutations) is sufficient to convert the cancer growth from a hormone-sensitive to a hormone-refractory disease (33).”
BackgroundSun, A., Shanmugam, I., Song, J., Terranova, P. F., Thrasher, J. B., & Li, B. (2007) · The Prostate · doi:10.1002/pros.20586 · Cited by 81
“Recently, we reported that high levels of GSK-3bY216 phosphorylationwas associatedwith aggressive prostate cancers and that GSK-3b activity is required for androgen receptor (AR) transactivation [6], which is a critical determinant in the progression of prostate cancer [7].”
BackgroundPhellinus linteus activates different pathways to induce apoptosis in prostate cancer cells
Zhu, T., Guo, J., Collins, L., Kelly, J., Xiao, Z. J., Kim, S.-H., & Chen, C.-Y. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603595 · Cited by 79
“Upon binding to the active androgen dihydrotestosterone (DHT), the receptor dissociates from the heat shock proteins, and translocates to the nucleus (Feldman and Feldman, 2001; Grossmann et al, 2001; Chen et al, 2004 ).”
BackgroundInfluentialSelf-citationIntranuclear organization and function of the androgen receptor
Black, B. E., & Paschal, B. M. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.09.006 · Cited by 87
Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer
Wetherill, Y. B., Hess-Wilson, J. K., Comstock, C. E. S., Shah, S. A., Buncher, C. R., Sallans, L., Limbach, P. A., Schwemberger, S., Babcock, G. F., & Knudsen, K. E. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0272 · Cited by 78
“Increased androgen receptor is both necessary and sufficient to render prostate cancer cells resistant to anti-androgen therapy, as amplified androgen receptor enhances the basal level response to low residual hormone as well as modifies the androgen receptor response to antagonists (42).”
BackgroundMounir, Z., Korn, J. M., Westerling, T., Lin, F., Kirby, C. A., Schirle, M., McAllister, G., Hoffman, G., Ramadan, N., Hartung, A., et al. (2016) · eLife · doi:10.7554/elife.13964 · Cited by 82
“Increased AR activity drives PC proliferation (Chen et al., 2004).”
BackgroundSaporita, A. J., Ai, J., & Wang, Z. (2007) · The Prostate · doi:10.1002/pros.20541 · Cited by 77
“These observations suggest that the loss of nuclear localization of ARA748T and ARR752Q in C4-2 cells may be due to impaired interaction with hsp90 rather than impaired binding to low levels of androgen.”
BackgroundInfluentialReiner, T., Parrondo, R. D., Pozas, A. D. L., Palenzuela, D. L., & Perez‐Stable, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056234 · Cited by 86
Stabilizing Androgen Receptor in Mitosis Inhibits Prostate Cancer Proliferation
Griend, D. J. V., Litvinov, I. V., & Isaacs, J. T. (2007) · Cell Cycle · doi:10.4161/cc.6.6.4028 · Cited by 78
Androgen receptor and prostate cancer
Richter, E., Srivastava, S. K., & Dobi, A. L. (2007) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500936 · Cited by 83
“50 These observations are consistent with reports demonstrating that increases in AR mRNA and protein levels are both necessary and sufficient to convert CaP growth from hormone-sensitive to a hormone-refractory stage, and is dependent on a functional AR ligand-binding domain”
BackgroundChen, S.-Y., Cai, C., Fisher, C. J., Zheng, Z., Omwancha, J., Hsieh, C.-L., & Shemshedini, L. (2006) · Oncogene · doi:10.1038/sj.onc.1209705 · Cited by 86
Deep, G., Oberlies, N. H., Kroll, D. J., & Agarwal, R. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm069 · Cited by 82
“Several studies by others and us in the last decade have demonstrated the pre-clinical efficacy of both silymarin and silibinin against various epithelial cancers including PCA (10–13), and their efficacy is currently being evaluated in cancer patients (14).”
BackgroundInfluentialTranslational and clinical implications of the genetic landscape of prostate cancer
Spratt, D. E., Zumsteg, Z. S., Feng, F. Y.-C., & Tomlins, S. A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.76 · Cited by 84
Tilki, D., Schaeffer, E. M., & Evans, C. P. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.11.013 · Cited by 80
“Furthermore, the authors found that AR antagonists showed agonistic activity in cells with increased AR levels (antagonist-agonist conversion) that was associated with alterations in the recruitment of co-activators and co-repressors to the promoters of AR target genes [14].”
BackgroundMethodInfluentialYang, Q., Fung, K.-M. A., Day, W., Kropp, B. P., & Lin, H. (2005) · Cancer Cell International · doi:10.1186/1475-2867-5-8 · Cited by 93
“The development of a more efficient delivery system, such as the lentiviral-based gene delivery system [41], may allow for further study of AR signaling in multiple prostate cell lines.”
BackgroundTiwari, R., Manzar, N., Bhatia, V., Yadav, A., Nengroo, M. A., Datta, D. B., Carskadon, S. L., Gupta, N., Sigouros, M., Khani, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14184-0 · Cited by 81
Gaballa, R., Ali, H. E. A., Mahmoud, M. O., Rhim, J. S., Ali, H. I., Salem, H. F., Saleem, M., Kandeil, M. A., Ambs, S., & Elmageed, Z. Y. A. (2020) · Cancers · doi:10.3390/cancers12082300 · Cited by 79
Bruno, R. D., Vasaitis, T. S., Gediya, L. K., Purushottamachar, P., Godbole, A. M., Ateş‐Alagöz, Z., Brodie, A. M. H., & Njar, V. C. O. (2011) · Steroids · doi:10.1016/j.steroids.2011.06.002 · Cited by 81
“Although strategies such as surgical or chemical castrations, which can effectively reduce serum testosterone levels have remained the most effective therapy for PCA for over 65 years [3], recent studies clearly show that prostate cancers may generate intracrine androgenic steroids and also become hypersensitive to lo…”
BackgroundImaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen
Ulmert, D., Evans, M. J., Holland, J. P., Rice, S. L., Wongvipat, J., Pettersson, K. S. I., Abrahamsson, P.-A., Scardino, P. T., Larson, S. M., Lilja, H. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0316 · Cited by 76
“We began in vivo studies by administering (89)Zr-5A10 to intact male mice inoculated with subcutaneous xenografts of LNCaP-AR [a PSA-positive prostate cancer model derived from parental LNCaP overexpressing wild-type AR (15)].”
BackgroundMethodSelf-citationTewari, A. K., Yardımcı, G. G., Shibata, Y., Sheffield, N. C., Song, L., Taylor, B. S., Georgiev, S., Coetzee, G. A., Ohler, U., Furey, T. S., et al. (2012) · Genome biology · doi:10.1186/gb-2012-13-10-r88 · Cited by 86
“AR expression results in context-specific transformation of prostate epithelial cells [1-5], and persistent AR signaling is implicated in the progression to castration-resistant prostate cancer [6-8].”
Sumiyoshi, T., Mizuno, K., Yamasaki, T., Miyazaki, Y., Makino, Y., Okasho, K., Li, X., Utsunomiya, N., Goto, T., Kobayashi, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40719-y · Cited by 78
Dong, Y., Zhang, H., Gao, A. C., Marshall, J. R., & Ip, C. C. Y. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0124 · Cited by 79
“(35) claimed that increased androgen receptor expression is both necessary and sufficient to convert prostate cancer growth from androgen-dependent to -independent and that androgen receptor antagonists may display agonistic activity in cells with elevated androgen receptor expression.”
BackgroundArdiani, A., Gameiro, S. R., Kwilas, A. R., Donahue, R. N., & Hodge, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.2429 · Cited by 78
“LNCaP cells stably overexpressing AR (LNCaP/AR(cs)) were a gift from Dr. Charles Sawyers (Memorial Sloan-Kettering Cancer Center, New York, NY) and were maintained in the recommended medium with 10% FBS [43].”
BackgroundKawamura, S., Sato, I., Wada, T., Yamaguchi, K., Li, Y., LI, D., Zhao, X., Ueno, S., Aoki, H., Tochigi, T., et al. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.83 · Cited by 76
“We do not know the mechanism of the NEU3 effects, but it has been suggested that increased AR expression converts even antagonists to weak agonists.(1,2) When AR were silenced to 10–15% the level of control cells, the cell growth rate was significantly reduced as compared with the cells having control AR shown in Figu…”
BackgroundResultYuan, X., Li, T., Wang, H., Zhang, T., Barua, M., Borgesi, R. A., Bubley, G. J., Lu, M. L., & Balk, S. P. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051047 · Cited by 79
The cyclin D1b splice variant: an old oncogene learns new tricks.
Knudsen, K. E. (2006) · Cell Division · doi:10.1186/1747-1028-1-15 · Cited by 93
“Moreover, deregulation of AR activity has been validated in tumor models to be sufficient for therapeutic bypass [87,88].”
BackgroundPersistent androgen receptor addiction in castration-resistant prostate cancer
Schweizer, M. T., & Yu, E. Y. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0225-2 · Cited by 85
“Chen and colleagues demonstrated that a number of prostate cancer cell lines will adaptively increase their AR expression as they are passaged in castrate mice over time, and that this overexpression of AR is sufficient to induce resistance to the effects of surgical castration as well as treatment with the first-gene…”
BackgroundResultn-3 Polyunsaturated Fatty Acids and Their Role in Cancer Chemoprevention
Gu, Z., Shan, K., Chen, H., & Chen, Y. Q. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-015-0043-9 · Cited by 87
Levine, P. M., Imberg-Kazdan, K., Garabedian, M. J., & Kirshenbaum, K. (2012) · Journal of the American Chemical Society · doi:10.1021/ja300170n · Cited by 76
AR-Signaling in Human Malignancies: Prostate Cancer and Beyond
Schweizer, M. T., & Yu, E. Y. (2017) · Cancers · doi:10.3390/cancers9010007 · Cited by 77
“A case report has also reported favorable outcomes when ADT was combined with radiation therapy in a patient with AR-positive salivary gland cancer [168].”
BackgroundInfluentialThe novel role of pyrvinium in cancer therapy
Momtazi‐borojeni, A. A., Abdollahi, E., Ghasemi, F., Caraglia, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26006 · Cited by 75
“key role of AR in the development of prostate cancer makes it a valuable therapeutic target for prostate cancer treatment (Chen et al., 2004; Taplin & Balk, 2004).”
BackgroundEnzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
Linder, S., van der Poel, H. G., Bergman, A. M., Zwart, W. T., & Preković, S. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0289 · Cited by 85
Accelerating precision medicine in metastatic prostate cancer
Mateo, J., McKay, R. R., Abida, W. M., Aggarwal, R. R., Alumkal, J. J., Alva, A. S., Feng, F. Y.-C., Gao, X. Y., Graff, J. N., Hussain, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00141-0 · Cited by 83
The developing role of receptors and adaptors
Massie, C. E., & Mills, I. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1882 · Cited by 74
“This is an important point given the hypothesis that recurrent prostate cancer results from androgen hypersensitivity rather than genuine androgen independenc”
BackgroundAttard, G., Sarker, D., Reid, A. H. M., Molife, R., Parker, C. C., & Bono, J. S. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603223 · Cited by 82
“Finally, the recent discovery of chromosomal translocations resulting in the upregulation of one of at least 3 ETS genes (ERG, ETV1, ETV4) may lead to novel agents for the treatment of this disease.”
BackgroundInfluentialAndrogen Action in Prostate Cancer
Basu, S., & Tindall, D. J. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0044-4 · Cited by 91
“The mechanism for this activity is attributed to an alteration in the coactivator assembly on the promoter of AR-dependent target genes [45].”
BackgroundInfluentialGuerrini, A., Tesei, A., Ferroni, C., Paganelli, G., Zamagni, A., Carloni, S., Donato, M. D., Castoria, G., Leonetti, C., Porru, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5005122 · Cited by 75
Targeting CDK9: a promising therapeutic opportunity in prostate cancer
Rahaman, M. H., Kumarasiri, M., Mekonnen, L. B., Yu, M., Diab, S., Albrecht, H., Milne, R. W., & Wang, S. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0299 · Cited by 80
“…cancer En d o cr in e- R el at ed C an ce r DOI: 10.1530/ERC-16-0299 http://erc.endocrinology-journals.org © 2016 Society for Endocrinology Printed in Great Britain Published by Bioscientifica Ltd. 23:12 (Chen et al. 2004) found consistent overexpression of AR only in castrate-resistant xenografts.”
BackgroundInfluentialSyntaxin 6‐mediated exosome secretion regulates enzalutamide resistance in prostate cancer
Peak, T. C., Panigrahi, G. K., Praharaj, P. P., Su, Y., Shi, L., Chyr, J., Rivera‐Chávez, J., Flores‐Bocanegra, L., Singh, R., Vander Griend, D. J., et al. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23129 · Cited by 74
“Enz‐resistant PCa cells also develop cross‐ resistance to abiraterone, an androgen synthesis inhibitor approved to treat metastatic hormone‐refractory PCa.7 At present, Enz‐ resistant hormone‐refractory PCa is a major clinical challenge, and novel strategies aimed at overcoming Enz resistance are urgently needed to im…”
InfluentialUo, T., Sprenger, C. C. T., & Plymate, S. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580617 · Cited by 88
Castilla, C., Congregado, B., Conde-Sánchez, J. M., López, R. A. M., Torrubia, F., Japón, M. Á., & Sáez, C. (2010) · Urology · doi:10.1016/j.urology.2010.05.045 · Cited by 73
Endocrinology in field studies: Problems and solutions for the experimental design
Fusani, L. (2008) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2008.04.016 · Cited by 86
“The reasons for the inversion are not fully understood yet, however it has been shown that antiandrogen can lead to a substantial upregulation of androgen receptor, which results in a hypersensitivization of tissues to very low concentration of androgen (Chen et al., 2004).”
BackgroundFrigo, D. E., Sherk, A. B., Wittmann, B. M., Norris, J. D., Wang, Q., Joseph, J. D., Toner, A. P., Brown, M. A., & McDonnell, D. P. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0010 · Cited by 75
“expression of KLF5 also appeared to sensitize LNCaP cells to lower levels of androgens, suggesting that patients with high KLF5 levels, and thus CXCR4, may be more prone to develop metastases from prostate cancers that have elevated AR activity, as is commonly seen in hormonerefractory diseases (38).”
BackgroundHo, Y., & Dehm, S. M. (2017) · Endocrinology · doi:10.1210/en.2017-00109 · Cited by 79
“This concept is also consistent with work showing that overexpression of AR protein can sensitize CRPC cells to castrate levels of androgens and can convert antagonists such as bicalutamide into weak agonists (12, 13).”
BackgroundResultGuo, Y. X., Cui, J. G., Ji, Z., Cheng, C., Zhang, K., Zhang, C., Chu, M., Zhao, Q., Yu, Z., Zhang, Y., et al. (2017) · Oncogene · doi:10.1038/onc.2017.240 · Cited by 73
Pawar, A., Gollavilli, P. N., Wang, S., & Asangani, I. A. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.011 · Cited by 83
Porter, B. A., Ortiz, M. A., Bratslavsky, G., & Kotula, L. (2019) · Cancers · doi:10.3390/cancers11121852 · Cited by 91
“It has been reported that treatment‐ induced point mutation, W741C, in full length‐AR allows bicalutamide to act as an AR agonist [53,55,56].”
BackgroundInfluentialHan, H. H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110595 · Cited by 86
Takayama, K., Suzuki, T., Tsutsumi, S., Fujimura, T., Urano, T., Takahashi, S., Homma, Y., Aburatani, H., & Inoue, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2949 · Cited by 78
“The first is enhancement of AR signaling caused by mutation, amplification of the AR gene or other mechanisms that allow for the activation of AR even with castration levels of serum testosterone [1, 8-10].”
Hsp90, the Concertmaster: Tuning Transcription
Khurana, N., & Bhattacharyya, S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00100 · Cited by 82
“It is observed that in hormone refractory or androgenindependent (AI) prostate cancer cells, a large pool of androgen receptor is translocated into the nucleus even in the absence of androgen and thus leads to the transcriptional activation of target genes resulting in tumor growth (11, 12).”
BackgroundTargeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
Lallous, N., Dalal, K., Cherkasov, A. R., & Rennie, P. S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140612496 · Cited by 79
“Notably, expression of AR-dependent genes, such as PSA and transmembrane protease serine 2 (TMPRSS2), is often reactivated in CRPC, despite low levels of circulating androgens, implying that AR transcriptional activity has become ligand-independent [50].”
BackgroundKim, Y.-R., Kim, I., Kang, T. W., Choi, C., Kim, K. K., Kim, M. S., Kim, K. K., & Jung, C. (2013) · Oncogene · doi:10.1038/onc.2013.404 · Cited by 72
Matsumoto, H., Yamamoto, Y., Shiota, M., Kuruma, H., Beraldi, E., Matsuyama, H., Zoubeidi, A., & Gleave, M. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0359 · Cited by 74
“The AR is the principle driver of CRPC (5), and is supported by ADTactivated growth factor signaling pathways (6), survival genes (7), and cytoprotective chaperone networks (8).”
BackgroundMass Spectrometry-based Expression Profiling of Clinical Prostate Cancer
Wright, M. E., Han, D. K. M., & Aebersold, R. H. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r500008-mcp200 · Cited by 73
“ling the growth of androgen-refractory PCa (75, 76).”
BackgroundMizokami, A., Koh, E., Izumi, K., Narimoto, K., Takeda, M., Honma, S., Dai, J., Keller, E. T., & Namiki, M. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-09-0070 · Cited by 72
“AR amplification, action of cytokines on the AR, induction of AR coactivators, or STAT-3 activation (Fujimoto et al. 2001, Harada et al. 2001, Chen et al. 2004) all can cause an androgen-hypersensitive state in PCa.”
BackgroundZhang, Y., Wang, Z. P., Ahmed, F., Banerjee, S., Li, Y., & Sarkar, F. H. (2006) · International Journal of Cancer · doi:10.1002/ijc.22077 · Cited by 72
“This could be partly due to the lack of effective therapies, resulting in high mortality of patients diagnosed with hormone refractory metastatic prostate cancer.(2,3) Thus, development of novel treatment strategies is urgently needed.”
BackgroundRetractedNUSAP1 promotes invasion and metastasis of prostate cancer
Gordon, C. A., Gong, X., Ganesh, D., & Brooks, J. D. (2017) · Oncotarget · doi:10.18632/oncotarget.15604 · Cited by 74
“NUSAP1 expression increases in response to androgen treatment in LNCaP cells [54]; however, NUSAP1 is associated with the mitotic spindle and androgen treatment of prostate epithelial cells induces proliferation.”
Androgen Receptor Activation by Gs Signaling in Prostate Cancer Cells
Kasbohm, E. A., Guo, R., Yowell, C. W., Bagchi, G., Kelly, P., Arora, P., Casey, P. J., & Daaka, Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414423200 · Cited by 81
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
Perner, S., Cronauer, M. V., Schrader, A. J., Klocker, H., Čulig, Z., & Baniahmad, A. (2015) · Oncotarget · doi:10.18632/oncotarget.4689 · Cited by 77
“Adaptive mechanisms of PCa cells include molecular alterations in response to androgen ablation leading to re-activation of the AR despite low circulating androgens after initial response to ADT [8].”
BackgroundInfluentialAndreu-Vieyra, C., Lai, J., Berman, B. P., Frenkel, B., Jia, L., Jones, P. A., & Coetzee, G. A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05934-11 · Cited by 72
“AR expression was also shown to be necessary and sufficient to convert androgen-sensitive prostate cancer to an ablation-resistant state (7).”
BackgroundThe Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP
Hamilton, M. P., Rajapakshe, K., Bader, D. A., Cerne, J. Z., Smith, E. A., Coarfa, C., Hartig, S. M., & McGuire, S. E. (2016) · Neoplasia · doi:10.1016/j.neo.2016.04.008 · Cited by 81
“The disease is primarily driven at all stages by activation of the androgen receptor (AR) [2,3].”
BackgroundEvolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
Antonarakis, E. S., & Armstrong, A. J. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.23 · Cited by 71
Functional evidence implicating S100P in prostate cancer progression
Basu, G. D., Azorsa, D. O., Kiefer, J., Rojas, A. M., Tüzmen, Ş., Barrett, M. T., Trent, J. M., Kallioniemi, O., & Mousses, S. (2008) · International Journal of Cancer · doi:10.1002/ijc.23447 · Cited by 76
“Interestingly, both AR and S100P are also found to be over-expressed in hormone refractory prostate tumors.(3,29) This”
BackgroundDiscovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
Guo, C., Linton, A., Kephart, S. E., Ornelas, M. A., Pairish, M., González, J., Greasley, S. E., Nagata, A., Burke, B. J., Edwards, M. P., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201059s · Cited by 71
PI3K-AKT-mTOR Pathway is Dominant over Androgen Receptor Signaling in Prostate Cancer Cells
Kaarbø, M., Mikkelsen, Ø., Malerød, L., Qu, S., Lobert, V. H., Akgul, G., Halvorsen, T., Mælandsmo, G. M., & Saatcioglu, F. (2010) · Analytical Cellular Pathology · doi:10.1155/2010/290643 · Cited by 85
Effects and mechanisms of pyrethroids on male reproductive system
Wang, Q., Shen, J., Zhang, R., Hong, J., Li, Z., Ding, Z., Wang, H.-X., Zhang, J., Zhang, M., & Xu, L. (2020) · Toxicology · doi:10.1016/j.tox.2020.152460 · Cited by 79
The vitamin D receptor as a therapeutic target
Campbell, M. J., & Adorini, L. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.5.735 · Cited by 70
“Targets (2006) 10(5) defined seven subfamilies, and within these the VDR is in the group 1 subfamily, sharing homology with the LXRs and FXR, and more distantly the PPARs (reviewed in [1,2]).”
BackgroundInfluentialMUC1 oncoprotein is a druggable target in human prostate cancer cells
Joshi, M. D., Ahmad, R., Yin, L., Raina, D., Rajabi, H., Bubley, G., Kharbanda, S., & Kufe, D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0646 · Cited by 72
“cells has been further supported by the targeting of AR function in in vitro and animal tumor models (29, 30).”
BackgroundDeregulation of a Hox Protein Regulatory Network Spanning Prostate Cancer Initiation and Progression
Chen, J. L., Li, J., Kiriluk, K. J., Rosen, A. M., Paner, G. P., Antic, T., Lussier, Y. A., & Griend, D. J. V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0373 · Cited by 72
“6 Protein-protein interaction network analysis and pathway enrichment To evaluate whether distinct derived gene signatures connected to cancer-related genes greater than expected by chance, we used a Single Protein Analysis of Network (SPAN) methodology (25-27).”
Shiota, M., Yokomizo, A., & Naito, S. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0232 · Cited by 72
“Many studies have shown that the progression of CRPC is associated with increased AR expression (Gregory et al. 1998, Zegarra-Moro et al. 2002, Chen et al. 2004, Scher & Sawyers 2005), which can be attributed to gene amplification, transcriptional up-regulation, translational up-regulation, and…”
BackgroundFerrari, A. C., Alumkal, J. J., Stein, M. N., Taplin, M., Babb, J. S., Barnett, E. S., Gómez-Pinillos, A., Liu, X., Moore, D. F., DiPaola, R. S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1589 · Cited by 71
“Mechanistically, it was shown that conformational changes in overexpressed flAR interfere with the binding and recruitment of the complement of coactivators and corepressors required for bicalutamide antagonist activity (20).”
BackgroundInfluentialHuntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors
Mills, I. G., Gaughan, L., Robson, C., Ross, T., McCracken, S., Kelly, J., & Neal, D. E. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200503106 · Cited by 71
“D ow nloaded from http://rupress.org/jcb/article-pdf/170/2/191/1320063/jcb1702191.pdf by guest on 10 M arch 2022 JCB • VOLUME 170 • NUMBER 2 • 2005192 factor, the androgen receptor (AR; Chen et al., 2004).”
BackgroundInfluentialThe evolving role of immune cells in prostate cancer
Wang, C., Zhang, Y., & Gao, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.027 · Cited by 81
Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer
Lucarelli, G. T., Rutigliano, M., Galleggiante, V., Giglio, A., Palazzo, S., Ferro, M., Simone, C., Bettocchi, C., Battaglia, M., & Ditonno, P. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1069711 · Cited by 75
“Moreover, much evidence has shown that CRPC continues to require AR signaling, despite the reduction in circulating androgen levels [85–97].”
BackgroundJi, Q., Chang, L., Stanczyk, F. Z., Ookhtens, M., Sherrod, A. E., & Stolz, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1593 · Cited by 70
“cause for androgen independence with increased sensitivity to low levels of androgens (9).”
Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer
da Silva, H. B., Amaral, E. P., Nolasco, E. L., de Victo, N. C., Atique, R., Jank, C. C., Anschau, V., Zerbini, L. F., & Correa, R. G. (2013) · Prostate Cancer · doi:10.1155/2013/920612 · Cited by 86
“NF-κB is associated with increased AR expression and higher binding activity in androgen-independent xenografts [69].”
Background
Metadata
- Authors
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Howard Hughes Medical Institute (US)
- University of Washington (US)
- Corresponding author
- Sawyers, Charles L
- Venue
- Nature Medicine
- Published
- 2003-12-21
- Volume
- 10
- Issue
- 1
- Pages
- 33-39
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2003955264
- Cited by
- 2,278
- References
- 50
- Citations by year
- 2026: 21 · 2025: 40 · 2024: 40 · 2023: 72 · 2022: 59 · 2021: 86 · 2020: 68 · 2019: 82 · 2018: 99 · 2017: 110 · 2016: 106 · 2015: 119 · 2014: 128 · 2013: 156 · 2012: 155
- FWCI
- 69.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- prostate cancer, antiandrogen resistance, androgen receptor, castration-resistant prostate cancer, androgen receptor ligand-binding domain, coactivator recruitment, corepressor recruitment, androgen receptor target genes
- MeSH terms
- Androgen Antagonists, Base Sequence, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, DNA Primers, Disease Progression, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.